Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Rare Pediatric Disease Drug & Multiple Myeloma Therapy Also Make The Grade
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
You may also be interested in...
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.